FindMyKOL
Clinical trialNCT07822919RecruitingPhase 1Interventional

A Study of AWT020 in Participants With Advanced Solid Tumors

NCT07822919 is a phase 1 interventional trial sponsored by Anwita Biosciences. As of 21 Nov 2026, it is recruiting participants. It studies AWT020 in Advanced Cancers (Solid Tumors). The registry lists an enrollment of 96 participants at 3 sites in 1 country. The registry lists a start date of 15 Oct 2026 and a primary completion date of 31 Jan 2029. One of its registered investigators has a FindMyKOL profile.

SponsorAnwita BiosciencesEnrollment96Advanced Cancers (Solid Tumors)
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07822919
FieldValue
Registry IDNCT07822919
StatusRecruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorAnwita Biosciences
Enrollment96
Registered sites3
Countries1
ConditionsAdvanced Cancers (Solid Tumors)
DrugsAWT020
Start15 Oct 2026
Primary completion31 Jan 2029
Study completion28 Feb 2029
Last update posted17 Nov 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is aimed at establishing the MTD and/or the RP2D for AWT020 monotherapy and to provide safety, tolerability, efficacy, PK, immunogenicity characteristics of AWT020.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Florida, United States1 site, 1 recruiting
  • Florida Clinical Trials Group

    Plantation

    Harshad Amin, MD
    Recruiting
Tennessee, United States1 site, 1 recruiting
  • Scri Oncology Partners

    Nashville

    Benjamin Garmezy, MD
    Recruiting
Virginia, United States1 site, 1 recruiting
  • Next Virginia

    Fairfax

    Alexander Spira, MD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginia: 1 site, 1 recruitingVA1MarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennessee: 1 site, 1 recruitingTN1North CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 site, 1 recruitingFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AWT020
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT07822919

Each answer restates registry values shown on this page.

What is NCT07822919?

NCT07822919 is a phase 1 interventional trial sponsored by Anwita Biosciences. It studies AWT020 in Advanced Cancers (Solid Tumors).

Is NCT07822919 recruiting?

As of 21 Nov 2026, it is recruiting participants. 3 of its 3 sites list their own status as recruiting.

Who leads NCT07822919?

The registry names Harshad Amin, MD (principal investigator, Florida Clinical Trials Group) as the overall official.

Where does NCT07822919 run?

The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT07822919 study?

The registered drug and biological interventions are AWT020.

When is NCT07822919 expected to complete?

The registry lists a primary completion date of 31 Jan 2029 and a study completion date of 28 Feb 2029. The sponsor last updated the record on 17 Nov 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.